G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Report 2026

G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview

• G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies market size has reached to $0.59 billion in 2025 • Expected to grow to $2.42 billion in 2030 at a compound annual growth rate (CAGR) of 32.9% • Growth Driver: Rising Myeloma Prevalence Drives Demand For The Market Due To Growing Patient Burden • Market Trend: Innovative Immunotherapy Approaches For Relapsed And Refractory Multiple Myeloma • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market?

G protein-coupled receptor family C group 5 member D (GPRC5D) targeted therapies are precision treatments designed to selectively recognize and attack cells expressing the GPRC5D protein, a receptor highly present on malignant plasma cells, especially in multiple myeloma. It helps to provide highly targeted cancer therapy that maximizes tumor elimination while minimizing harm to healthy tissues. The main types of G protein-coupled receptor family C group 5 member D (GPRC5D) targeted therapies include monoclonal antibodies, bispecific antibodies, chimeric antigen receptor (CAR-T) cell therapies, and other therapy types. Monoclonal antibodies refer to laboratory-produced antibodies designed to specifically target GPRC5D proteins on cancer cells to inhibit tumor growth and stimulate immune response. These therapies are used for indications such as multiple myeloma, solid tumors, and other indications. They use technologies including precision medicine approaches, molecular Targeted Therapy, cancer immunotherapy platforms, and biopharmaceutical drug delivery systems. They are administered via intravenous, subcutaneous, and other routes of administration, and are used by end users including hospitals, specialty clinics, research institutes, and other end users.

What Is The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Growth Forecast?

The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $2.42 billion in 2030 at a compound annual growth rate (CAGR) of 32.9%. The growth in the forecast period can be attributed to increasing regulatory approvals for targeted biologics, rising demand for personalized cancer treatments, expansion of next-generation immunotherapy platforms, growing investments in precision medicine ecosystems, increasing adoption of biomarker-based therapy selection. Major trends in the forecast period include increasing development of bispecific antibody therapies, rising focus on gprc5d biomarker-driven patient selection, growing adoption of car-t cell platforms, expansion of precision oncology clinical pipelines, enhanced integration of companion diagnostics.

Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Segmentation

1) By Therapy Type: Monoclonal Antibodies; Bispecific Antibodies; Chimeric Antigen Receptor (CAR-T) Cell Therapies; Other Therapy Types 2) By Indication: Multiple Myeloma; Solid Tumors; Other Indications 3) By Technology: Precision Medicine Approaches; Molecular Targeted Therapy; Cancer Immunotherapy Platforms; Biopharmaceutical Drug Delivery Systems 4) By Route Of Administration: Intravenous; Subcutaneous; Other Routes Of Administration 5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users Subsegments: 1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Murine Monoclonal Antibodies 2) By Bispecific Antibodies: Dual Targeting Bispecific Antibodies; Cross Linking Bispecific Antibodies; Immune Cell Engaging Bispecific Antibodies; Cytotoxic Bispecific Antibodies 3) By Chimeric Antigen Receptor (CAR-T) Cell Therapies: Autologous Car T Cell Therapies; Allogeneic Car T Cell Therapies; Next Generation Car T Cell Therapies; Gene Edited Car T Cell Therapies 4) By Other Therapy Types: Targeted Small Molecule Drugs; Receptor Specific Inhibitors; Injectable Biologics; Oral Targeted Therapeutics

What Is The Driver Of The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market?

The rising myeloma prevalence is expected to propel the growth of the GPRC5D-targeted therapies market going forward. Myeloma is a cancer of plasma cells in the bone marrow that disrupts normal blood cell production and can cause bone damage, anemia, and kidney problems. The incidence of myeloma is increasing partly due to aging populations, because the risk of developing plasma cell disorders rises with age as genetic mutations accumulate over time. GPRC5D-targeted therapies help treat myeloma by binding to the GPRC5D protein on malignant plasma cells and directing the immune system, especially T cells, to selectively kill these cancerous cells, while sparing most normal cells. For instance, in January 2026, according to the American Cancer Society, a US-based professional organization, in 2026, the United States is expected to record approximately 36,000 new cases of multiple myeloma, including 20,150 cases in men and 15,850 cases in women, with around 10,850 deaths anticipated, comprising 5,780 men and 5,070 women. Therefore, the rising myeloma prevalence is driving the growth of the GPRC5D-targeted therapies market.

Key Players In The Global G Protein‑Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

Major companies operating in the g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies market are Johnson And Johnson, F. Hoffmann‑La Roche AG., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Bristol Myers Squibb Company, Genmab A/S, Genentech Inc., Simcere Zaiming Biotechnology Co. Ltd., Innovent Biologics Inc., Essen Biotech Co. Ltd., Nanjing IASO Biotechnology Co. Ltd., CARsgen Therapeutics Holdings Limited, Oricell Therapeutics Co. Ltd., Integral Molecular Inc., Overland Therapeutics Inc., Qilu Pharmaceutical Co. Ltd., Leads Biolabs Ltd., ShanghAI Yake Biotechnology Co. Ltd., Guangzhou Bio‑gene Technology Co. Ltd.

Global G Protein‑Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Trends and Insights

Major companies operating in the GPRC5D targeted therapies market are focusing on developing innovative solutions, such as bispecific T cell engagers, to enhance immune-mediated targeting of cancer cells and improve treatment efficacy. A bispecific T-cell engager (BiTE) is a type of immunotherapy molecule designed to connect T-cells directly to cancer cells by binding both simultaneously, activating the T-cells to destroy the targeted cancer cells. For instance, in August 2023, Johnson & Johnson, a US-based healthcare company, received an approval from the European Commission of TALVEY (talquetamab), Janssen's bispecific antibody therapy targeting GPRC5D, for relapsed and refractory multiple myeloma (RRMM) in patients after at least three prior therapies. It is a first-in-class bispecific T-cell engager targeting GPRC5D on multiple myeloma cells and CD3 on T cells to treat relapsed/refractory multiple myeloma in heavily pretreated patients. Its key purpose is providing durable responses (ORR >70% in trials) after at least four prior therapies, with advantages including subcutaneous dosing, sustained quality-of-life benefits, and efficacy even post-bispecifics or CAR-T, filling an unmet need in late-line disease.

What Are Latest Mergers And Acquisitions In The G Protein‑Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market?

In May 2023, LaNova Medicines Ltd., a China-based clinical-stage biotechnology company, partnered with AstraZeneca Plc to advance the development of novel oncology therapies through joint clinical programs. Through this partnership, AstraZeneca aims to obtain worldwide rights to research, develop, and commercialize LM-305, a preclinical-stage GPRC5D-targeting antibody-drug conjugate (ADC) for the treatment of relapsed or refractory multiple myeloma. AstraZeneca plc, a UK-based company that develops GPRC5D-targeted therapies for the treatment of multiple myeloma.

Regional Insights

North America was the largest region in the GPRC5D targeted therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the G Protein‑Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market?

The G protein‑coupled receptor family C group 5 member D (GPRC5D) targeted therapies market consists of revenues earned by entities by providing services such as clinical trial management, personalized therapy design, patient screening and biomarker testing, regulatory consulting, and post-marketing support. The market value includes the value of related goods sold by the service provider or included within the service offering. The G protein‑coupled receptor family C group 5 member D (GPRC5D) targeted therapies market also includes sales of monoclonal antibodies, antibody drug conjugates, targeted small molecule drugs, receptor-specific inhibitors, injectable biologics, oral targeted therapeutics, infusion kits, diagnostic companion kits, laboratory reagents, and vials and prefilled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the G Protein‑Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Report 2026?

The g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.